Biomark Diagnostics Inc. (BMKDF)

Market Cap	24.52M
Revenue (ttm)	113.57K
Net Income (ttm)	-1.26M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Average Volume	2,973
Open	0.2540
Previous Close	0.2540
Day's Range	0.2530 - 0.2540
52-Week Range	0.1170 - 0.2680
Beta	-0.35
RSI	56.54
Earnings Date	Nov 27, 2025

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: BMKDF

Financial Performance

In 2024, Biomark Diagnostics's revenue was 154,216, a decrease of -5.52% compared to the previous year's 163,220. Losses were -1.93 million, 35.0% more than in 2023.

Financial numbers in CAD